Friday, 16 October 2026European Markets

SES Stock Went Down By Over 11% So Far On Monday

Loading stream...

(vianews) - shares of ses (cac 40: sesg.pa) dropped by a staggering 11.73% to €4.93 at 11:07 est on monday, following the last session's downward trend. cac 40 is rising 0.86% to €7,274.97, following the last session's downward trend. this seems, at the moment, a somewhat up trend exchanging session today.

ses's last close was €5.59, 38.03% under its 52-week high of €9.02.

about ses

ses s.a. provides satellite-based data transmission capacity and ancillary services worldwide. it offers content connectivity solutions, including network spanning satellite and ground infrastructure to create, deliver, and manage video and data solutions. the company also provides data connectivity services through its fleet of geostationary earth orbit and medium earth orbit satellites to government, aeronautical, maritime, telecommunications companies, mobile network operators, and cloud industries. the company also offers video services, which includes end-to-end managed services to audience; and provides multi-screen and multi-device viewing experiences on linear channels, video-on-demand, streaming platforms, and social media sites for broadcasters, platform operators, and sports organizations. in addition, it provides linear video aggregation and distribution, such as direct-to-home, direct-to-cable, and internet protocol tv households; hybrid video platform solutions; channel management solutions comprising playout; and live feeds and multiple redundancy content. the company was founded in 1985 and is headquartered in betzdorf, luxembourg.

earnings per share

as for profitability, ses has a trailing twelve months eps of €-0.16.

dividend yield

as stated by morningstar, inc., the next dividend payment is on apr 18, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 8.9%.

sales growth

ses's sales growth is 8.1% for the current quarter and negative 3% for the next.

more news about ses (sesg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com